Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pure Femme Tablets
- Development stage
- Phase 2
- Lead developer
- Pure Green Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Sublingual
01
Overview
Pure Femme Tablets is a sublingual tablet developed by Pure Green, designed for the treatment of dysmenorrhea and associated pain symptoms. It is a combination drug containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene, beta-caryophyllene, humulene, linalool, and limonene, along with peppermint oil.
- Brand names
- Pure Femme Tablets
02
Targets
CNR1 (Cannabinoid receptor 1)ER (Estrogen receptor)FAAHGPR55 (G protein-coupled receptor 55)PPARG (Peroxisome proliferator-activated receptor gamma)PR (Progesterone receptor)TRPV1 (Transient receptor potential cation channel subfamily V member 1)PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on Pure Femme Tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pure Femme Tablets.